NASH Pipeline Includes Six Candidates That Have Reached Phase III
Our infographic offers a snapshot of the trial endpoints and mechanisms of action of the compounds at the front of the race to treat the enormous NASH market.
You may also be interested in...
Intercept said its commercial groundwork in NASH centered on identifying doctors who treat patients with advanced fibrosis and talking to payers about the importance of preventing cirrhosis.
Other NASH registration trails have targeted fibrosis, but Galectin's mostly-resolved discussions with US FDA will allow the belapectin program to focus of signs and symptoms of the disease.
Galectin faces a dual challenge - do its planned trial well and trust that the study design will lead the galectin-3 inhibitor belapectin to a niche position in NASH.